hydroxychloroquine and Eye Disorders
hydroxychloroquine has been researched along with Eye Disorders in 48 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"To investigate the usefulness of hydroxychloroquine (HCQ) dose-loading to increase the percentage of responders or rate of response in treating rheumatoid arthritis (RA)." | 9.09 | Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension. ( Baethge, B; Botstein, GR; Caldwell, J; Dietz, F; Ettlinger, R; Furst, DE; Golden, HE; Lindsley, H; McLaughlin, GE; Moreland, LW; Roberts, WN; Rooney, TW; Rothschild, B; Sack, M; Sebba, AI; Weisman, M; Welch, KE; Yocum, D, 1999) |
"A dose-response relationship for hydroxychloroquine (HCQ), in terms of the proportion of patients achieving the Paulus 20% criteria for improvement, had previously been observed in patients with rheumatoid arthritis (RA) receiving a 6-week loading regimen of 400, 800, or 1,200 mg HCQ daily." | 7.71 | Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. ( Baethge, BA; Botstein, GR; Caldwell, J; Dietz, F; Ettlinger, R; Furst, DE; Gibbs, JP; Golden, HE; Lindsley, H; McLaughlin, GE; Moreland, LW; Munster, T; Roberts, WN; Rooney, TW; Rothschild, B; Sack, M; Sebba, AI; Shen, D; Weisman, M; Welch, KE; Yocum, D, 2002) |
"Hydroxychloroquine is a widely used medication for various clinical conditions mainly rheumatological and dermatological autoimmune diseases e." | 5.72 | Early onset monocular hydroxychloroquine maculopathy in a systemic lupus erythematosus patient with history of central retinal artery occlusion: a case report. ( Ameen Ismail, A; Hatata, RM; Sadek, SH, 2022) |
"To investigate the usefulness of hydroxychloroquine (HCQ) dose-loading to increase the percentage of responders or rate of response in treating rheumatoid arthritis (RA)." | 5.09 | Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension. ( Baethge, B; Botstein, GR; Caldwell, J; Dietz, F; Ettlinger, R; Furst, DE; Golden, HE; Lindsley, H; McLaughlin, GE; Moreland, LW; Roberts, WN; Rooney, TW; Rothschild, B; Sack, M; Sebba, AI; Weisman, M; Welch, KE; Yocum, D, 1999) |
"Hydroxychloroquine and quinacrine are frequently used to treat rheumatic diseases." | 5.01 | Are the Current Recommendations for Chloroquine and Hydroxychloroquine Screening Appropriate? ( Samson, CM; Schwartzman, S, 2019) |
"The antimalarial drugs chloroquine (CQ) and hydroxychloroquine (HCQ) have been used for decades to treat rheumatic diseases." | 4.87 | Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature. ( Koren, G; Osadchy, A; Ratnapalan, T, 2011) |
"A dose-response relationship for hydroxychloroquine (HCQ), in terms of the proportion of patients achieving the Paulus 20% criteria for improvement, had previously been observed in patients with rheumatoid arthritis (RA) receiving a 6-week loading regimen of 400, 800, or 1,200 mg HCQ daily." | 3.71 | Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. ( Baethge, BA; Botstein, GR; Caldwell, J; Dietz, F; Ettlinger, R; Furst, DE; Gibbs, JP; Golden, HE; Lindsley, H; McLaughlin, GE; Moreland, LW; Munster, T; Roberts, WN; Rooney, TW; Rothschild, B; Sack, M; Sebba, AI; Shen, D; Weisman, M; Welch, KE; Yocum, D, 2002) |
"The development of our RMA approach was motivated by a currently relevant clinical question: is ocular toxicity and vision compromise a side effect of hydroxychloroquine therapy? At the time of designing this study, hydroxychloroquine was a leading candidate in the treatment of coronavirus disease (COVID-19)." | 2.66 | Artificial Intelligence for Rapid Meta-Analysis: Case Study on Ocular Toxicity of Hydroxychloroquine. ( Chow, T; Martin, NA; Michelson, M; Minton, S; Ross, M; Tee Qiao Ying, A, 2020) |
" A new study indicates that toxicity is not as rare as once believed, but depends critically on daily dosage and duration of use, as well as other risk factors." | 2.52 | A Critical Review of the Effects of Hydroxychloroquine and Chloroquine on the Eye. ( Brézin, AP; Costedoat-Chalumeau, N; Dunogué, B; Jallouli, M; Le Guern, V; Leroux, G; Marmor, MF; Melles, RB; Morel, N; Piette, JC, 2015) |
"Quinacrine does not cause retinopathy, but it has more cutaneous side effects than the other two agents." | 2.36 | Antimalarials. ( Koranda, FC, 1981) |
"Hydroxychloroquine is a widely used medication for various clinical conditions mainly rheumatological and dermatological autoimmune diseases e." | 1.72 | Early onset monocular hydroxychloroquine maculopathy in a systemic lupus erythematosus patient with history of central retinal artery occlusion: a case report. ( Ameen Ismail, A; Hatata, RM; Sadek, SH, 2022) |
" We revised the antimalarials use in Rheumatology, their utility, doses, adverse events and risk factors as cumulate doses, ideal daily doses, renal function and ophthalmological reviews recommendations." | 1.31 | [Eye toxicity of antimalarial agents]. ( Cabana Vázquez, M; Graña Gil, J; Sánchez Meizoso, MO; Vázquez González, A, 2002) |
"Surgical treatment of cataracts, band keratopathy, and glaucoma achieved uniformly discouraging results." | 1.25 | Ocular manifestations of juvenile rheumatoid arthritis. ( Bellows, AR; Bienfang, DC; Chylack, LT; Stillman, JS, 1975) |
Research
Studies (48)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 23 (47.92) | 18.7374 |
1990's | 3 (6.25) | 18.2507 |
2000's | 6 (12.50) | 29.6817 |
2010's | 8 (16.67) | 24.3611 |
2020's | 8 (16.67) | 2.80 |
Authors
Authors | Studies |
---|---|
Jorge, AM | 1 |
Mancini, C | 1 |
Zhou, B | 1 |
Ho, G | 1 |
Zhang, Y | 1 |
Costenbader, K | 1 |
Choi, HK | 1 |
Ameen Ismail, A | 1 |
Sadek, SH | 1 |
Hatata, RM | 1 |
Kellner, U | 3 |
Kellner, S | 3 |
Weinitz, S | 3 |
Farmand, G | 3 |
Dias-Santos, A | 1 |
Tavares Ferreira, J | 1 |
Pinheiro, S | 1 |
Cunha, JP | 1 |
Alves, M | 1 |
Papoila, AL | 1 |
Moraes-Fontes, MF | 1 |
Proença, R | 1 |
Gegúndez-Fernández, JA | 1 |
Zarranz-Ventura, J | 1 |
Garay-Aramburu, G | 1 |
Muñoz-Negrete, FJ | 1 |
Mendicute Del Barrio, J | 1 |
Pablo-Júlvez, L | 1 |
García-Delpech, S | 1 |
López-Alemany, A | 1 |
Arnalich-Montiel, F | 1 |
Cordero-Coma, M | 1 |
Cárceles, JA | 1 |
Michelson, M | 1 |
Chow, T | 1 |
Martin, NA | 1 |
Ross, M | 1 |
Tee Qiao Ying, A | 1 |
Minton, S | 1 |
Carter, KL | 1 |
Do, DV | 1 |
Menet, J | 1 |
Agrinier, N | 1 |
Dufrost, V | 1 |
Conart, JB | 1 |
Wahl, D | 1 |
Duprez, KA | 1 |
Zuily, S | 1 |
Lin, TC | 1 |
Marmor, MF | 3 |
Barbhaiya, M | 1 |
Guan, H | 1 |
Chen, SK | 1 |
Feldman, CH | 1 |
Costenbader, KH | 1 |
Dammacco, R | 1 |
Procaccio, P | 1 |
Racanelli, V | 1 |
Vacca, A | 1 |
Dammacco, F | 1 |
Schwartzman, S | 1 |
Samson, CM | 1 |
Costedoat-Chalumeau, N | 1 |
Dunogué, B | 1 |
Leroux, G | 1 |
Morel, N | 1 |
Jallouli, M | 1 |
Le Guern, V | 1 |
Piette, JC | 1 |
Brézin, AP | 1 |
Melles, RB | 1 |
McCune, WJ | 1 |
Gonzalez-Rivera, T | 1 |
Kowalczyk, JP | 1 |
Ricotti, CA | 1 |
de Araujo, T | 1 |
Drosou, A | 1 |
Nousari, CH | 1 |
Heravian, J | 1 |
Saghafi, M | 1 |
Shoeibi, N | 1 |
Hassanzadeh, S | 1 |
Shakeri, MT | 1 |
Sharepoor, M | 1 |
Osadchy, A | 1 |
Ratnapalan, T | 1 |
Koren, G | 1 |
Munster, T | 1 |
Gibbs, JP | 1 |
Shen, D | 1 |
Baethge, BA | 1 |
Botstein, GR | 2 |
Caldwell, J | 2 |
Dietz, F | 2 |
Ettlinger, R | 2 |
Golden, HE | 2 |
Lindsley, H | 2 |
McLaughlin, GE | 2 |
Moreland, LW | 2 |
Roberts, WN | 2 |
Rooney, TW | 2 |
Rothschild, B | 2 |
Sack, M | 2 |
Sebba, AI | 2 |
Weisman, M | 2 |
Welch, KE | 2 |
Yocum, D | 2 |
Furst, DE | 2 |
KERSLEY, GD | 1 |
Samanta, A | 1 |
Goh, L | 1 |
Bawendi, A | 1 |
Mavrikakis, I | 1 |
Mavrikakis, E | 1 |
Shearer, RV | 1 |
Dubois, EL | 1 |
Koranda, FC | 1 |
Tanenbaum, L | 1 |
Tuffanelli, DL | 1 |
Baethge, B | 1 |
Jones, SK | 1 |
Fielder, A | 1 |
Graham, E | 1 |
Jones, S | 1 |
Silman, A | 1 |
Tullo, A | 1 |
Motta, M | 1 |
Tincani, A | 1 |
Faden, D | 1 |
Zinzini, E | 1 |
Chirico, G | 1 |
Graña Gil, J | 1 |
Cabana Vázquez, M | 1 |
Vázquez González, A | 1 |
Sánchez Meizoso, MO | 1 |
Klein, SA | 1 |
Tomaro, AJ | 1 |
Chylack, LT | 1 |
Bienfang, DC | 1 |
Bellows, AR | 1 |
Stillman, JS | 1 |
Maksymowych, W | 1 |
Russell, AS | 1 |
Sammartino, JP | 1 |
Soll, DB | 1 |
Sugar, J | 1 |
Henkind, P | 2 |
Gold, DH | 1 |
Laaksonen, AL | 1 |
Koskiahde, V | 1 |
Juva, K | 1 |
Nylander, U | 1 |
David-Chaussé, J | 1 |
David-Chaussé, F | 1 |
Picot, C | 1 |
Laporte, G | 1 |
Lagoarde, J | 1 |
Dehais, J | 1 |
Crews, SJ | 1 |
Alfieri, R | 1 |
Sole, P | 1 |
Sassaman, FW | 1 |
Cassidy, JT | 1 |
Alpern, M | 1 |
Maaseidvaag, F | 1 |
Zvaifler, NJ | 1 |
Sarmela, T | 1 |
Kajander, A | 1 |
Bertrand, JJ | 2 |
Debeyre, N | 1 |
Kahn, MF | 1 |
Ryckewaert, A | 1 |
Carr, RE | 1 |
Rothfield, N | 1 |
Siegel, IM | 1 |
Chiari, JJ | 1 |
Freyberg, RH | 1 |
Arden, GB | 1 |
Kolb, H | 1 |
Clinical Trials (1)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Hydroxychloroquine in Unexplained Recurrent Pregnancy Loss ,Double Blinded Randomized Controlled Trial .[NCT05237843] | Phase 1 | 70 participants (Anticipated) | Interventional | 2022-03-01 | Not yet recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Reviews
10 reviews available for hydroxychloroquine and Eye Disorders
Article | Year |
---|---|
Recommendations for eye care during the alarm state by the coronavirus disease pandemic COVID-19.
Topics: Antimalarials; Asymptomatic Diseases; Betacoronavirus; Blood Safety; Chloroquine; Contact Lenses; Co | 2020 |
Artificial Intelligence for Rapid Meta-Analysis: Case Study on Ocular Toxicity of Hydroxychloroquine.
Topics: Artificial Intelligence; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Eye; Eye Disease | 2020 |
Are the Current Recommendations for Chloroquine and Hydroxychloroquine Screening Appropriate?
Topics: Antimalarials; Chloroquine; Eye Diseases; Humans; Hydroxychloroquine; Patient Care Management; Rheum | 2019 |
A Critical Review of the Effects of Hydroxychloroquine and Chloroquine on the Eye.
Topics: Animals; Chloroquine; Drug Dosage Calculations; Eye Diseases; Humans; Hydroxychloroquine; Lupus Eryt | 2015 |
Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature.
Topics: Antimalarials; Child; Chloroquine; Databases, Factual; Eye; Eye Diseases; Female; Humans; Hydroxychl | 2011 |
Antimalarials.
Topics: Antimalarials; Chloroquine; DNA; Eye Diseases; Humans; Hydroxychloroquine; Quinacrine; RNA; Skin Dis | 1981 |
Antimalarial agents. Chloroquine, hydroxychloroquine, and quinacrine.
Topics: Abnormalities, Drug-Induced; Anti-Inflammatory Agents; Chloroquine; DNA; Eye Diseases; Female; Hemat | 1980 |
Ocular toxicity and hydroxychloroquine: guidelines for screening.
Topics: Antimalarials; Eye Diseases; Humans; Hydroxychloroquine; Mass Screening; Practice Guidelines as Topi | 1999 |
Antimalarials in rheumatology: efficacy and safety.
Topics: Antimalarials; Arthritis, Rheumatoid; Biomechanical Phenomena; Chloroquine; Clinical Trials as Topic | 1987 |
Ocular manifestations of rheumatic disorders. Natural and iatrogenic.
Topics: Adrenal Cortex Hormones; Arteritis; Arthritis, Juvenile; Arthritis, Rheumatoid; Chloroquine; Conjunc | 1973 |
Trials
5 trials available for hydroxychloroquine and Eye Disorders
Article | Year |
---|---|
A comparative study of the usefulness of color vision, photostress recovery time, and visual evoked potential tests in early detection of ocular toxicity from hydroxychloroquine.
Topics: Adult; Antirheumatic Agents; Color Vision; Early Diagnosis; Evoked Potentials, Visual; Eye Diseases; | 2011 |
Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response | 1999 |
Antimalarials in rheumatology: efficacy and safety.
Topics: Antimalarials; Arthritis, Rheumatoid; Biomechanical Phenomena; Chloroquine; Clinical Trials as Topic | 1987 |
Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus. A clinical study with determination of serum concentrations of chloroquine and hydroxychloroquine.
Topics: Adolescent; Adult; Arthritis, Juvenile; Child; Child, Preschool; Chloroquine; Clinical Trials as Top | 1974 |
The prevention of drug-induced retinopathies.
Topics: Adolescent; Adult; Aged; Chloroquine; Clinical Trials as Topic; Eye; Eye Diseases; Female; Humans; H | 1966 |
Other Studies
34 other studies available for hydroxychloroquine and Eye Disorders
Article | Year |
---|---|
Hydroxychloroquine Dose per Ophthalmology Guidelines and the Risk of Systemic Lupus Erythematosus Flares.
Topics: Antirheumatic Agents; Dose-Response Relationship, Drug; Eye Diseases; Humans; Hydroxychloroquine; Lu | 2022 |
Early onset monocular hydroxychloroquine maculopathy in a systemic lupus erythematosus patient with history of central retinal artery occlusion: a case report.
Topics: Adult; Antirheumatic Agents; Eye Diseases; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, | 2022 |
[Exogenously induced retinopathies].
Topics: Drug-Related Side Effects and Adverse Reactions; Eye Diseases; Humans; Hydroxychloroquine; Pentosan | 2022 |
[Exogenously induced retinopathies].
Topics: Drug-Related Side Effects and Adverse Reactions; Eye Diseases; Humans; Hydroxychloroquine; Pentosan | 2022 |
[Exogenously induced retinopathies].
Topics: Drug-Related Side Effects and Adverse Reactions; Eye Diseases; Humans; Hydroxychloroquine; Pentosan | 2022 |
[Exogenously induced retinopathies].
Topics: Drug-Related Side Effects and Adverse Reactions; Eye Diseases; Humans; Hydroxychloroquine; Pentosan | 2022 |
[Exogenously induced retinopathies].
Topics: Drug-Related Side Effects and Adverse Reactions; Eye Diseases; Humans; Hydroxychloroquine; Pentosan | 2022 |
[Exogenously induced retinopathies].
Topics: Drug-Related Side Effects and Adverse Reactions; Eye Diseases; Humans; Hydroxychloroquine; Pentosan | 2022 |
[Exogenously induced retinopathies].
Topics: Drug-Related Side Effects and Adverse Reactions; Eye Diseases; Humans; Hydroxychloroquine; Pentosan | 2022 |
[Exogenously induced retinopathies].
Topics: Drug-Related Side Effects and Adverse Reactions; Eye Diseases; Humans; Hydroxychloroquine; Pentosan | 2022 |
[Exogenously induced retinopathies].
Topics: Drug-Related Side Effects and Adverse Reactions; Eye Diseases; Humans; Hydroxychloroquine; Pentosan | 2022 |
Ocular involvement in systemic lupus erythematosus patients: a paradigm shift based on the experience of a tertiary referral center.
Topics: Adult; Antirheumatic Agents; Drug-Related Side Effects and Adverse Reactions; Eye Diseases; Female; | 2020 |
Drs. Carter and Do reply.
Topics: Eye Diseases; Humans; Hydroxychloroquine | 2021 |
Ophthalmologic manifestations in patients with antiphospholipid antibodies: Beware of iatrogenic complications.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Eye Disease | 2021 |
Baseline Retinal Examinations in Patients With Systemic Lupus Erythematosus Newly Initiating Hydroxychloroquine Treatment in a US Medicaid Systemic Lupus Erythematosus Population, 2000-2010.
Topics: Adult; Antirheumatic Agents; Cohort Studies; Eye Diseases; Female; Humans; Hydroxychloroquine; Lupus | 2018 |
Hydroxychloroquine During Cancer Therapy.
Topics: Breast Neoplasms; Drug Therapy, Combination; Eye Diseases; Humans; Hydroxychloroquine | 2019 |
Ocular Involvement in Systemic Lupus Erythematosus: The Experience of Two Tertiary Referral Centers.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Drug-Related Side Effects and Adverse Reactions; Eye | 2018 |
Should very low doses of hydroxychloroquine and quinacrine be employed in combination for long-term maintenance of remission in systemic lupus to reduce the risk of ocular toxicity?
Topics: Antimalarials; Dose-Response Relationship, Drug; Drug Therapy, Combination; Eye Diseases; Follow-Up | 2015 |
"Strawberry gums" in sarcoidosis.
Topics: Adult; Antibodies, Monoclonal; Eye Diseases; Female; Gingival Hyperplasia; Humans; Hydroxychloroquin | 2008 |
Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Eye Diseases; Gastrointestinal Dise | 2002 |
THE VALUE AND DANGERS OF ANTIMALARIAL THERAPY IN ARTHRITIS WITH SPECIAL RELATION TO OPHTHALMIC COMPLICATIONS.
Topics: Antimalarials; Arthritis; Arthritis, Rheumatoid; Chloroquine; Corneal Opacity; Electroretinography; | 1964 |
Are evidence-based guidelines being followed for the monitoring of ocular toxicity of hydroxychloroquine? A nationwide survey of practice amongst consultant rheumatologists and implications for clinical governance.
Topics: Antirheumatic Agents; Evidence-Based Medicine; Eye Diseases; Guideline Adherence; Humans; Hydroxychl | 2004 |
Are evidence-based guidelines being followed for the monitoring of ocular toxicity of hydroxychloroquine? A nationwide survey of practice amongst consultant rheumatologists and implications for clinical governance. Comment on the article by Samanta et al.
Topics: Antirheumatic Agents; Eye Diseases; Guideline Adherence; Humans; Hydroxychloroquine; Practice Guidel | 2004 |
Ocular changes induced by long-term hydroxychloroquine (plaquenil) therapy.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Child; Cornea; Eye Diseases; Female; Fluoresceins; H | 1967 |
Royal College of Ophthalmologists guidelines: ocular toxicity and hydroxychloroquine.
Topics: Antirheumatic Agents; Dermatologic Agents; Drug Administration Schedule; Eye Diseases; Humans; Hydro | 1998 |
Antimalarial agents in pregnancy.
Topics: Antimalarials; Eye Diseases; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Infant, Newborn; | 2002 |
[Eye toxicity of antimalarial agents].
Topics: Adult; Antimalarials; Chloroquine; Eye Diseases; Female; Humans; Hydroxychloroquine; Lupus Erythemat | 2002 |
Lupus erythematosus profundus: review of the literature and report of case.
Topics: Adult; Biopsy; Eye Diseases; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Discoid | 1975 |
Ocular manifestations of juvenile rheumatoid arthritis.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Age Factors; Arthritis, Juvenile; Atropine; Cataract; Ch | 1975 |
Ocular toxicity of systemic drugs.
Topics: Adrenal Cortex Hormones; Antitubercular Agents; Chloroquine; Contraceptives, Oral; Digitalis; Eye Di | 1985 |
Ocular side effects of systemic therapy of cutaneous diseases.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Antimetabolites; Chloroquine; Eye Diseases; Humans; | 1985 |
Ocular damage in chloroquine therapy.
Topics: Adult; Arthritis, Rheumatoid; Child; Chloroquine; Color Perception Tests; Color Vision Defects; Corn | 1967 |
[Evaluation of a practical use of synthetic antimalarials in the treatment of rheumatoid polyarthritis].
Topics: Aged; Antimalarials; Arthritis, Rheumatoid; Aspirin; Chloroquine; Eye Diseases; Female; Follow-Up St | 1971 |
On very short wavelength electroretinography. An original technique of diagnosis in infraclinical synthetic antimalarial retinopathies.
Topics: Adult; Aged; Antimalarials; Chloroquine; Diagnosis, Differential; Electroretinography; Eye Diseases; | 1969 |
Electroretinography in patients with connective tissue diseases treated with hydroxychloroquine.
Topics: Arthritis, Rheumatoid; Color Perception Tests; Electroretinography; Eye Diseases; Eye Movements; Hum | 1970 |
Antimalarial treatment of rheumatoid arthritis.
Topics: Antimalarials; Arthritis, Rheumatoid; Chloroquine; Eye Diseases; Humans; Hydroxychloroquine; Retina | 1968 |
[Ophthalmic side effects of chloroquine in patients with rheumatoid arthritis].
Topics: Arthritis, Rheumatoid; Chloroquine; Cornea; Eye Diseases; Female; Humans; Hydroxychloroquine; Male | 1968 |
[Supervision of the eyes during prolonged treatment with synthetic antimalarial drugs. Results in 237 patients followed up for 4 years on the average].
Topics: Antimalarials; Chloroquine; Corneal Opacity; Drug Tolerance; Electroretinography; Eye Diseases; Hydr | 1968 |
Ocular toxicity of antimalarial drugs. Long-term follow-up.
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Electrooculography; Electror | 1968 |
[Transitory retinopathy caused by prolonged treatment with hydroxychloroquine sulfate].
Topics: Antimalarials; Arthritis, Rheumatoid; Eye Diseases; Female; Humans; Hydroxychloroquine; Lupus Erythe | 1965 |
Antimalarial therapy and early retinal changes in patients with rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Chloroquine; Electrooculography; Eye Diseases; Femal | 1966 |
[Electroretinography in 83 patients treated with synthetic antimalarials].
Topics: Adolescent; Adult; Aged; Antimalarials; Child; Chloroquine; Electroretinography; Eye Diseases; Femal | 1966 |